MERCI Retriever

Global Thrombectomy Devices Market: Growth, Trends and Forecasts (2020-2025) - ResearchAndMarkets.com

Retrieved on: 
Friday, July 10, 2020

The "Global Thrombectomy Devices Market: Growth, Trends and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Thrombectomy Devices Market: Growth, Trends and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering.
  • The growing burden of strokes across the world is demanding innovative products with high efficacy, leading to growth in the sales of stent retrievers for effective thrombectomy related procedures, thus driving the thrombectomy devices market.
  • Mechanical thrombectomy devices comprise a wide number of endovascular tools cleared for removing thrombi from the neurovasculature in acute ischemic stroke patients.
  • Two of the first generation mechanical thrombectomy devices include the Merci Retriever system by Stryker and the Penumbra Aspiration device by Penumbra.

Perfuze Receives Breakthrough Device Designation Status from U.S. Food and Drug Administration (FDA) for Millipede CIS (Clot Ingestion System)

Retrieved on: 
Wednesday, August 7, 2019

Perfuze , a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has been granted Breakthrough Device Designation by the U.S. FDA for its Millipede CIS technology.

Key Points: 
  • Perfuze , a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has been granted Breakthrough Device Designation by the U.S. FDA for its Millipede CIS technology.
  • Millipede CIS is an innovative catheter technology that is designed to remove clots from the brain following an acute ischemic stroke.
  • The designation recognizes the novelty of the Millipede technology and its potential to offer significant advantages over existing alternatives for treatment of acute ischemic stroke.
  • Breakthrough Device Designation from the FDA is granted to certain medical devices that provide for a more effective treatment of life-threatening or irreversibly debilitating diseases.

Medtech Company Perfuze Raises €3 Million in Seed Round

Retrieved on: 
Tuesday, January 29, 2019

Perfuze , a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has closed a 3 million seed investment round.

Key Points: 
  • Perfuze , a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has closed a 3 million seed investment round.
  • An ischemic stroke occurs when a blood vessel in the brain is blocked by a clot, preventing blood flow.
  • Perfuze has a technology with the potential to significantly improve outcomes for stroke patients, says John Yianni, Partner at Earlybird.
  • We are delighted to offer our financial and commercial support in helping this exciting company grow and get its life-saving technology to market.

CERENOVUS Receives FDA Clearance For Next Generation Stent Retriever Device Used To Treat Ischemic Stroke

Retrieved on: 
Monday, May 21, 2018

IRVINE, Calif., May 21, 2018 /PRNewswire/ --CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EMBOTRAP II Revascularization Device, a next generation stent retriever used to capture and remove life-threatening blood clots from the brain following an ischemic stroke.

Key Points: 
  • IRVINE, Calif., May 21, 2018 /PRNewswire/ --CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EMBOTRAP II Revascularization Device, a next generation stent retriever used to capture and remove life-threatening blood clots from the brain following an ischemic stroke.
  • "CERENOVUS is committed to advancing treatment with evidence-based solutions so that fewer and fewer people are affected by the ravages of stroke."
  • The EMBOTRAP II Revascularization Device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within eight hours of symptom onset.
  • CERENOVUS offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke.